10-Q

(註冊人的主要執行辦公室地址，包括郵政編碼和電話號碼，包括區域代碼)

請勾選以下選項以表示申報人（1）已提交證券交易法1934年第13條或15(d)條所要求提交的所有報告，且在過去12個月中（或申報人需要提交此類報告的較短期間）已提交；（2）已受到過去90天內此類提交要求的限制。是 ☒ 否 ☐

請打勾號表明註冊人是否根據《S-t條例405條規定（本章節232.405號）的規定，在過去12個月內（或註冊人需要提交此類文件的更短期限內），已提交每個交互數據文件。是 ☒ 不 ☐

勾選表示登記人是大型加速申報人、加速申報人、非加速申報人、較小型申報公司或新興成長公司。詳細定義請參閱《交易所法》第1202條中“大型加速申報人”、“加速申報人”、“較小型申報公司”和“新興成長公司”的定義。

如果是新興成長型企業，在符合任何依據證券交易法第13(a)條所提供的任何新的或修改的財務會計準則的遵循的延伸過渡期方面，是否選擇不使用核准記號進行指示。☐

以核准標記指示，表明登記者是否屬於殼公司（依據交易所法規第120億2項之定義）。是 ☐ 否 ☒

截至2024年11月1日，登記人持有 2,959,645 截至2024年7月30日，申報人持有184,769,862股普通股。

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies

Description of Business

Oncternal Therapeutics, Inc. (the “Company” or “Oncternal”), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company’s clinical pipeline includes ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers, ONCT-808, a CAR T (chimeric antigen receptor T-cells) product candidate that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (“ROR1”), and zilovertamab, a humanized monoclonal antibody that binds to ROR1. Oncternal’s program activities previously included ONCT-216, an investigational small molecule designed to inhibit the E26 Transformation Specific (“ETS”) family of oncoproteins.

Recent Developments - Strategic Alternatives

On September 12, 2024, the Company announced that its Board decided to discontinue the Company’s clinical trials evaluating ONCT-534 and ONCT-808 as well as all other product development activities, and to begin exploring strategic alternatives to maximize the value of the Company’s assets for its stockholders. The Company commenced a reduction-in-force beginning in September 2024, and is continuing to assess further cost reduction measures as its operational and strategic direction evolves. As part of the review of strategic alternatives, the Company may consider options such as asset sales or out-licensing opportunities for existing programs and merger, reverse merger or other business combination opportunities. There can be no assurance any transaction will result from the evaluation of strategic alternatives.

Principles of Consolidation

The condensed consolidated financial statements (the “financial statements”) include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the financial statements.

Going Concern

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven.

As of September 30, 2024, the Company had $14.6 million in cash, cash equivalents, and short-term investments, no debt and an accumulated deficit of $223.2 million. In connection with the Company’s September 12, 2024 announcement regarding the evaluation of strategic alternatives as well as the capital required for continuing development efforts, the Company has discontinued the clinical development of ONCT-534 and ONCT-808, while certain nonclinical research and manufacturing activities continue. As a result, the Company will continue to incur research and development expenses in connection with clinical trial closing costs and the completion of its nonclinical and manufacturing projects. From its inception, the Company has incurred recurring operating losses and negative cash flows from operations. The Company has concluded that the balance of cash, cash equivalents and short-term investments will not be sufficient to fund its planned expenditures and meet its obligations for the twelve months following the financial statement issuance date without raising additional funding, liquidating assets, or making changes to its operating plans or programs to reduce expenses. As a result, there is substantial doubt about the Company’s ability to continue as a going concern for twelve months following the issuance date of these financial statements. The financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

The Company expects to continue to incur net losses for the foreseeable future. The Company may seek additional funding to support its evaluation or implementation of strategic alternatives, which may be through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be unable to consummate a strategic transaction and it may decide to pursue a dissolution or liquidation.

As of April 2, 2024, the Company’s at-the-market (“ATM”) equity offering program expired. Through April 2, 2024, the Company had sold 457,342 shares of common stock for net proceeds of $10.8 million under the ATM program.

The Company's requirement or ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, the strategic alternatives the Company is able to identify, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.

Nasdaq Listing and Reverse Stock Split

On April 4, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the closing bid price for the Company’s common stock had closed below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”).

On January 8, 2024, the Company effected a 1-for-20 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, the Company regained compliance with the Nasdaq listing rules. Each of the Company’s shareholders received one new share of common stock for every 20 shares such shareholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company’s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock was not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company’s outstanding common stock options and warrants, and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data, common stock options and warrants included in these financial statements, including the exercise price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

Basis of Presentation

The accompanying interim financial statements are unaudited. The unaudited financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and with generally accepted accounting principles in the United States of America (“GAAP”). These unaudited financial statements have been prepared on the same basis as the audited, consolidated financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2023, filed with the SEC on its Annual Report on Form 10-K on March 7, 2024. The results presented in these unaudited financial statements are not indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Use of Estimates

The Company’s financial statements are prepared in accordance with GAAP. The preparation of the financial statements and accompanying notes requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine accruals for clinical trial and research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of Level 1 financial instruments in the fair value hierarchy (see Note 6 – Fair Value) and include cash in readily available checking accounts, money market accounts and commercial paper.

Short-term Investments

Short-term investments consist of U.S. treasury notes and bills, certificates of deposit, commercial paper and U.S. government sponsored enterprise securities with maturities of less than one year from the balance sheet date and are debt securities considered to be Level 1 and Level 2 financial instruments in the fair value hierarchy (see Note 6 – Fair Value). The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified all of its marketable securities at September 30, 2024 and December 31, 2023 as “available-for-sale” pursuant to ASC 320 Investments – Debt and Equity Securities. The Company records available-for-sale securities at fair value as determined by prices for identical or similar securities, with the unrealized gains and losses included as a separate component of accumulated comprehensive income (loss). In accordance with policy, the Company does not invest in or hold equity securities in its investment portfolio.

The Company adjusts the cost of available-for-sale debt securities for amortization of premiums or accretion of discounts to maturity. The Company includes interest and dividends on securities classified as available-for-sale in interest income. Such amortization and accretion are included in interest income. The cost of securities sold is based on the specific identification method. Realized gains or losses on available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company records unrealized gains and losses on available-for-sale marketable securities as a component of comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders’ equity on the balance sheets.

The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in short-term investments in the accompanying balance sheets. The Company’s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which the Company determines the accrued interest will not be collected.

The Company evaluates short-term investments for other-than-temporary impairment at the balance sheet date. Factors considered in determining whether a loss is other-than temporary include how significant the decline in value is as a percentage of the original cost, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company’s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered. As of September 30, 2024, there were no impairment charges on short-term investments.

The Company obtains the fair value of its available-for-sale marketable securities from a professional pricing service. The fair values of available-for-sale marketable securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank. The service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service or mathematical calculations. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, credit spreads, current market and contractual prices for the underlying instruments or debt, as well as other relevant economic measures.

Deferred Compensation

Deferred compensation represents the accrual of retention bonuses for certain executives and certain other members of senior management. The retention bonuses were entered into in connection with the waiver of annual cash performance bonuses of such personnel for the year ended December 31, 2023 and a temporary reduction of the chief executive officer’s salary from April 2023 through December 2024.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Research and Development Expenses and Accruals

Research and development expenses consist of costs incurred for the Company’s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process and development costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.

The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying balance sheets as prepaid expenses and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities and all clinical trial expenses are included in research and development expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.

Fair Value Measurements

The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as an exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:

Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, and accrued compensation. The carrying amounts of the Company’s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has short-term investments that are measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented (see Note 6).

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):


	September 30,
	2024		2023
Warrants to purchase common stock		170,521		170,521
Common stock options		643,358		550,600
Restricted stock unit awards		—		18,557
Total		813,879		739,678

Accounting Standards Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting – Improvements to Reportable Segment Disclosures (Topic 280), which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. Topic 280 includes amendments which a) introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker(CODM), b) extend certain annual disclosures to interim periods, c) clarify single reportable segment entities must apply ASC 280 in its entirety, d) permit more than one measure of segment profit or loss to be reported under certain conditions, and e) require disclosure of the title and position of the CODM. This update is effective for all public entities beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 will be applied retrospectively and early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.

Balance Sheet Details

Prepaid and other consist of the following:


	September 30,		December 31,
	2024		2023
Research and development	$	—	$	312
Clinical trials		—		294
Insurance		507		478
Other prepaid expenses		18		88
Related party receivable (see Note 4)		81		139
Grant and other receivable		263		493
	$	869	$	1,804

Accrued liabilities consist of the following:


	September 30,		December 31,
	2024		2023
Research and development	$	30	$	146
Clinical trials		1,776		2,018
Legal fees		164		134
Compensation		592		1,579
Severance compensation		1,024		—
Deferred compensation		1,467		—
Other		11		—
	$	5,064	$	3,877

Short-term Investments

The Company invests in available-for-sale marketable securities consisting of money market funds, commercial paper, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities.

Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of September 30, 2024 and December 31, 2023 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows:


		As of September 30, 2024
	Maturity (in years)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Market Value
Short-term investments:
U.S. Treasury debt securities	1 or less	$	1,499	$	—	$	—		$	1,499
Total short-term investments		$	1,499	$	—	$	—		$	1,499

		As of December 31, 2023
	Maturity (in years)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Market Value
Short-term investments:
U.S. Treasury debt securities	1 or less	$	23,840	$	4	$	—		$	23,844
Commercial Paper	1 or less		2,738		—		(1	)		2,737
U.S. Government Agency	1 or less		977		—		—			977
Total short-term investments		$	27,555	$	4	$	(1	)	$	27,558

The Company determined there were no other-than-temporary declines in the value of any available-for-sale securities as of September 30, 2024 and December 31, 2023. All the Company’s available-for-sale marketable securities mature within one year. The Company has no allowance for credit losses as of September 30, 2024 and December 31, 2023. During the nine months ended September 30, 2024 and 2023, the Company recognized an unrealized loss of $2 and loss of $9, respectively, in the accompanying statements of operations and comprehensive loss. Accrued interest receivable on available-for-sale securities was $10 at September 30, 2024 and $15 at December 31, 2023. The Company has not written off any accrued interest receivable in any of the periods presented in these financial statements.


Maturity of lease liabilities	Operating Leases
2024	$	50
2025		150
Total lease payments		200
Less imputed interest		(9	)
Total lease liability		191
Less current portion of lease liability		(191	)
Lease liability, long-term	$	—

Related Party Transactions

Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (“SPH USA”) entered into a Materials and Supply and Services Agreement (“SPH USA Services Agreement”), pursuant to which the Company and SPH USA executed various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018 (see Note 5). During 2023, the Company sold $520 of materials to SPH USA which was recorded as an offset to ONCT-216 operating expenses. As of September 30, 2024 and December 31, 2023, the Company had $81 and $139, respectively, in amounts receivable from SPH USA related to statements of work. SPH USA is the Company’s largest stockholder and an affiliate of one of the Company’s former directors, who served until the 2024 annual meeting on stockholders on June 20, 2024.

Restructuring Actions

In September 2024, the Company announced a workforce reduction in order to reduce its operating expenses and focus its efforts on strategic alternatives. As a result, the Company made estimates and judgements regarding its future plans, including future employee termination costs to be incurred in conjunction with involuntary separations when such separations are probable and estimable. In the third quarter of 2024, the Company recorded a pre-tax severance expense of $1.1 million, $0.7 million in research and development expense and $0.4 million in general and administrative expenses for the three and nine months ended September 30, 2024. Such amount was paid in October 2024 and is included within accrued liabilities on the Condensed Consolidated Balance Sheets.

spend annually through 2021. Under the Regents License Agreement, the Company recorded: (a) $30 in license maintenance fees as research and development expense for the three months ended September 30, 2024 and 2023, respectively, and $30 and $35 for each of the nine months ended September 30, 2024 and 2023, respectively, and (b) $36 and none in patent costs as general and administrative expense for the three months ended September 30, 2024 and 2023, respectively, and $0.2 million and a nominal amount for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company believes it has met its obligations under the Regents License Agreement.

The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15th anniversary of the first commercial sale of a licensed product. The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable, and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least 60 days’ written notice.

Effective January 1, 2022, the Company entered into a Research Agreement (the “Research Agreement”) with the Regents for further research on the ROR1 therapeutic development program. Under this four-year agreement that expires on December 31, 2025, the Regents will have an aggregate budget of $1.6 million, with quarterly payments of $125 in 2022, $131 in 2023, and $138 in 2024 and 2025. The Company recorded $0.1 million in research and development expenses under the Research Agreement for each of the three months ended September 30, 2024 and 2023, and $0.4 million for each of the nine months ended September 30, 2024 and 2023. Such costs are includable as part of the Company’s annual diligence obligations under the Regents License Agreement.

The National Institutes of Health (“NIH”) Grant Awards

The NIH has awarded the Company three research and development grants for up to $4.1 million to support preclinical activities for the Company’s ONCT-534 and ONCT-216 programs, including $1.0 million payable to subawardees. Under the terms of the grants, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the nine months ended September 30, 2024, the Company received $2.1 million in award payments, recorded $1.9 million in grant revenue and had $0.3 million in an unbilled grant receivable. During the nine months ended September 30, 2023, the Company received $0.4 million in award payments from the NIH, and recorded $0.5 million in grant revenue, and had $0.2 million in an unbilled grant receivable.

SPH USA, a Related Party

License and Development Agreement (“LDA”)

In November 2018, and as amended in August 2020, the Company entered into the LDA with SPH USA for: (i) the territory of the People’s Republic of China, Hong Kong, Macau, and Taiwan (“Greater China”), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company’s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.

The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy. There has been no significant activity under this agreement for each of the nine months ended September 30, 2024 and 2023 (see Note 4).

Contingent Value Rights Agreement

Pursuant to the GTx merger agreement entered into in June 2019 (the “Merger”), the Company, a representative of holders of the Contingent Value Rights (“CVRs”), and Computershare, Inc. as rights agent, entered into the Contingent Value Rights Agreement (as amended November 1, 2021, the “CVR Agreement”). Pursuant to the CVR Agreement, the Company’s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company’s common stock held immediately prior to the Merger.

As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i) 50% of certain net proceeds received by the Company during the 15-year period after the closing of the Merger (the “CVR Term”) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the 10-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period); and (ii) 5% of net sales of products

Fair Value

As of September 30, 2024 and December 31, 2023, the following fair value hierarchy table presents the Company’s financial assets measured at fair value on a recurring basis:


	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
As of September 30, 2024
Short-term investments:
U.S. Treasury debt securities	$	1,499	$	—	$	1,499	$	—
Total assets measured at fair value	$	1,499	$	—	$	1,499	$	—


	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
As of December 31, 2023
Short-term investments:
U.S. Treasury debt securities	$	23,844	$	10,912	$	12,932	$	—
Commercial Paper		2,737		—		2,737		—
U.S. Government Agency		977		—		977		—
Total assets measured at fair value	$	27,558	$	10,912	$	16,646	$	—

Stockholders’ Equity

ATM Program

In December 2021, the Company entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC, pursuant to which the Company was able to offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $50.0 million. On April 2, 2024, the ATM program expired. During 2024, the Company did not sell shares of common stock under the ATM program. On March 8, 2024, the Company filed a new shelf registration statement on Form S-3 (No. 333-277795) which was declared effective by the Securities and Exchange Commission on May 1, 2024.

Common Stock Warrants

A summary of warrant activity and changes in warrants outstanding is presented below:


	Number of Shares Underlying Warrants		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)
Balance at December 31, 2023		170,521	$	74.00		1.94
Issued / Exercised / Forfeited / Expired		—	$	—		—
Balance at September 30, 2024		170,521	$	74.00		1.18

As of September 30, 2024 and December 31, 2023, all warrants met the criteria for classification in stockholders’ equity.

Equity Incentive Plans

Stock Option Awards

Contemporaneous with the Merger closing: (i) Oncternal’s 2015 Equity Incentive Plan, as amended (“2015 Plan”) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (“2019 Plan”) under which the sum of: (a) 97,708 shares of common stock, and (b) an annual increase on the first day of each calendar year beginning January 1, 2020, and ending on and including January 1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as is determined by the board of directors, are reserved for issuance.

In July 2015, Oncternal adopted the 2015 Plan which provided for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a four-year period. Certain grants vested based on the achievement of development or regulatory milestones and the 2015 Plan was terminated as to new grant awards in June 2019.

The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire ten years from the date of grant and vest over a four-year period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.

In February 2021, the Company’s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules. As amended in 2021, the Inducement Plan has reserved 140,000 shares of common stock to be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual’s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of the 2019 Plan.

As of September 30, 2024, 154,314 shares remain available for issuance under the 2019 Plan and Inducement Plan. A summary of the Company’s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:



	Number of Options			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2023		548,073		$	56.51
Granted		191,875		$	9.07
Forfeited		(96,590	)	$	28.44
Outstanding at September 30, 2024		643,358		$	47.89		6.2	$	—
Options vested and expected to vest as of September 30, 2024		643,358		$	47.89		6.2	$	—
Options vested and exercisable as of September 30, 2024		413,182		$	63.61		4.8	$	—

For the nine months ended September 30, 2024 and 2023, the weighted average grant date fair value per share of option grants was $7.56 and $14.20, respectively. The intrinsic value is calculated as the difference between the fair value of the Company’s common stock at the time of the option exercise and the exercise price of that stock option. For the nine months ended September 30, 2024 and 2023, no stock options were exercised.

Restricted Stock Unit Awards

Restricted stock unit awards (“RSUs”) are rights to receive shares of the Company’s common stock upon satisfaction of specific vesting conditions. Issued RSUs generally vested over an eighteen month to two-year period. RSU activity under Equity Incentive Plans is summarized as follows:



	Number of Restricted Stock Units			Weighted-Average Remaining Contractual Term (in years)		Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2023		18,557			0.1	$	28.32
Vested		(18,557	)		—	$	28.32
Nonvested and expected to vest as of September 30, 2024		—			—	$	—

The fair value of RSUs vested during the nine months ended September 30, 2024 was $0.2 million.

Stock-Based Compensation Expense

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, were as follows:


	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2024		2023			2024			2023
Risk-free interest rate		—		4.1	%		4.3	%		4.1	%
Expected volatility		—		102.8	%		107.2	%		100.4	%
Expected term (in years)		—		6.1			6.0			6.0
Expected dividend yield		—		—	%		—	%		—	%

Expected volatility. During 2023, the expected volatility assumption was based on a blend of volatilities of the Company’s share price and a peer group of similar companies whose share prices are publicly available. The volatility of the Company’s shares price was measured using the closing share price beginning June 10, 2019, the date of the closing of the Merger, through the current period. The peer group was developed based on companies in the life sciences industry with comparable characteristics to the Company including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. Effective January 1, 2024, the Company elected to remove peer group companies and calculates its expected volatility assumption solely on the volatility of the Company’s historical share prices using the closing share price beginning June 10, 2019 through the current period.

Expected term. The expected term represents the period of time that options are expected to be outstanding. Due to limited historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.

Risk-free interest rate. The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.

Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.

RSU awards represent rights to receive shares of common stock contingent upon satisfaction of specific vesting conditions. The stock-based compensation expense for these awards was determined using the closing price on the grant date applied to the total number of shares that were anticipated to fully vest.

Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
Research and development	$	918	$	903	$	2,324	$	2,909
General and administrative		936		814		2,272		2,373
	$	1,854	$	1,717	$	4,596	$	5,282

As of September 30, 2024, the unrecognized compensation cost related to non-vested stock options was $3.5 million, which is scheduled to be recognized over a weighted-average period of 1.9 years.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance is as follows:


	September 30, 2024
Common stock warrants		170,521
Common stock options issued and outstanding		643,358
Common stock available for issuance under the Inducement Plan and 2019 Plan		154,314
		968,193

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with: (i) our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the period ended September 30, 2024, and (ii) our audited financial statements and notes thereto for the year ended December 31, 2023 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2023. Except as otherwise indicated herein or as the context otherwise requires, references in this Quarterly Report to “Oncternal” “the Company,” “we,” “us” and “our” refer to Oncternal Therapeutics, Inc., a Delaware corporation.

On September 12, 2024, we announced that our Board decided to discontinue our clinical trials evaluating ONCT-534 and ONCT-808 as well as all other product development activities, and to begin exploring strategic alternatives to maximize the value of our assets for our stockholders. We commenced a reduction-in-force beginning in September 2024, and will continue to assess further cost reduction measures as our operational and strategic direction evolves. As part of the review of strategic alternatives, we may consider options such as asset sales or out-licensing opportunities for existing programs and merger, reverse merger or other business combination opportunities. There can be no assurance any transaction will result from our evaluation of strategic alternatives.

We caution that trading in our securities is highly speculative and poses substantial risks. Trading prices for our securities may bear little or no relationship to the actual value realized, if any, by holders of our securities. Accordingly, we urge caution with respect to existing and future investments in our securities.

This Quarterly Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategies and plans, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. These forward-looking statements are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including those described in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, our prior Quarterly Reports on Form 10-Q, and in Part II, Item 1A, “Risk Factors” of this Quarterly Report. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

We are a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for patients with cancers with critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on prostate cancer and hematological malignancies. Our pipeline includes:

Since the inception of Oncternal Therapeutics, Inc. in 2013, we have devoted most of our resources to organizing and staffing, business planning, raising capital, acquiring product candidates and securing related intellectual property rights and advancing ONCT-534, ONCT-808, zilovertamab and ONCT-216 clinical and preclinical development programs. Through September 30, 2024, we have funded our operations primarily through: (i) gross proceeds of $136.3 million from the issuance of common stock, (ii) gross proceeds of $49.0 million from the issuance of convertible preferred stock, (iii) receipt of $14.5 million in subaward grant payments from UC San Diego, and (iv) cash proceeds of $18.3 million received in connection with the closing of the merger with GTx, Inc. in June 2019 (the "GTx Merger"). As of September 30, 2024, we had cash, cash equivalents and short-term investments of $14.6 million and no debt.

We have incurred net losses in each year since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss was $25.4 million for the nine months ended September 30, 2024 and we had an accumulated deficit of $223.2 million as of September 30, 2024. Substantially all of our net losses have resulted from costs incurred in connection with: (i) advancing our research and development programs, (ii) general and administrative costs associated with our operations, including the costs associated with operating as a public company, and (iii) in-process research and development costs associated with the GTx Merger.

On September 12, 2024, we announced that our Board decided to discontinue our clinical trials evaluating ONCT-534 and ONCT-808 as well as all other product development activities, and to begin exploring strategic alternatives to maximize the value of our assets for our stockholders, which may include asset sales, licensing or other transactions relating to our development program or a merger, reverse merger, acquisition, or other business combination opportunities. In connection with the exploration of strategic alternatives, we commenced a reduction-in-force beginning in September 2024, and will continue to assess further cost reduction measures as our operational and strategic direction evolves. As a result of this announcement, we expect our research and development expenses to decrease significantly as we discontinue our clinical research and development activities. We will continue to incur research and development expenses in connection with clinical trial closing costs and the completion of certain ongoing nonclinical research and manufacturing activities.

As of September 30, 2024, we have the following potential purchase obligations for which the timing and/or likelihood of occurrence is unknown; however, if such claims arise in the future, they could have a material effect on our financial position, results of operations, and cash flows.

Our future capital requirements will depend on many factors, including our Board's decisions regarding strategic alternatives.

Management concluded that the balance of cash, cash equivalents and short-term investments may not be sufficient to fund our planned expenditures and meet our obligations for at least the twelve months following the financial statement issuance date without entering into one or more collaborations or raising additional funding or making changes to operating plans or programs to reduce expenses. As a result, there is substantial doubt about our ability to continue as a going concern for twelve months following the issuance date of the condensed consolidated financial statements as of September 30, 2024. We believe that our cash, cash equivalents and short-term investments provide sufficient cash to fund our projected operating requirements into the first quarter of 2025.

Our grant revenue is derived from research and development grants from the National Institutes of Health (NIH).

The NIH has awarded us three research and development grants for up to $4.1 million to support preclinical activities for our ONCT-534 and ONCT-216 programs, including $1.0 million payable to subawardees. Under the terms of the grant awards, we are entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and we are required to provide periodic progress performance reports. During the nine months ended September 30, 2024, we received $2.1 million in award payments, recorded $1.9 million in grant revenue and had $0.3 million in an unbilled grant receivable. During the nine months ended September 30, 2023, we received $0.4 million in award payments, recorded $0.5 million in grant revenue and had $0.2 million in unbilled grant receivable.

Research and development expenses consist primarily of costs incurred for the development of ONCT-534, ONCT-808, zilovertamab, and ONCT-216, which include:

We accrue all research and development costs in the period for which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred and then expensed as the related goods are delivered and as services are performed. Any unearned advances would be refunded when known.

We expect our research and development expenses to significantly decrease as we discontinue our clinical research and development activities but will continue to incur research and development expenses in connection with clinical trial closing costs and the completion of certain ongoing manufacturing and nonclinical activities.

Our direct research and development expenses are tracked by product candidate and consist primarily of external costs, such as fees paid under third-party license agreements and to outside consultants, contract research organizations (CROs), contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by product candidate unless we can include them as subaward costs.

General and administrative expenses consist primarily of personnel-related costs, insurance costs, facility costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. Personnel-related costs consist of salaries, benefits and non-cash stock-based compensation. We expect our general and administrative expenses will fluctuate based on our Board's decisions regarding strategic alternatives.

Interest income consists of interest earned on our cash, cash equivalents and short-term investments, which primarily consist of money market funds and U.S. Treasury securities.

The following table summarizes our condensed consolidated results of operations for the periods indicated:

Grant revenue was $0.5 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. The increase of $0.3 million was primarily due to the timing of NIH grant activities.

The following table summarizes our research and development expenses for the periods indicated:

Research and development expenses for each of the three months ended September 30, 2024 and 2023 were $6.4 and $7.5 million, respectively. The decrease of $1.0 million was primarily due to a $0.8 million decrease in direct product candidate expenses and a $0.2 million decrease in unallocated expenses.

Direct expenses for ONCT-534 increased $1.4 million for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to an increase in manufacturing and clinical activities associated with the initiation of our Phase 1/2 clinical study of ONCT-534 in the third quarter of 2023. Such study was discontinued in the latter part of the third quarter of 2024.

Direct expenses for ONCT-808 decreased $0.7 million for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the discontinuance of our clinical trial in the third quarter of 2024.

Direct expenses for zilovertamab decreased $1.9 million for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to lower clinical trial activity and manufacturing costs associated with the reprioritization of this program in April 2023. Such study activities were completed in the third quarter of 2024.

Direct expenses for ONCT-216 increased $0.4 million for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to a $0.5 million sale of manufacturing materials to Shanghai Pharmaceutical (USA) Inc. (SPH USA) in 2023. Costs incurred in 2024 were substantially offset by NIH grant revenue.

Unallocated research and development expenses decreased $0.2 million for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to lower personnel-related expenses resulting from our headcount reductions as the year-to-date accrued bonuses were reversed in total and significantly offset by severance costs incurred. Excluding potential future severance costs while our strategic direction evolves, unallocated research and development expenses are expected to decrease in future periods as our research and development activities are being discontinued with a reduced headcount.

General and administrative expenses for each of the three months ended September 30, 2024 and 2023 were $2.7 million and $3.1 million, respectively. The decrease of $0.4 million was primarily due to lower personnel-related expenses resulting from our headcount reductions as the year-to-date accrued bonuses were reversed in total and only partially offset by severance costs incurred, board compensation stopped being accrued or paid effective July 1, 2024, corporate insurance and legal expenses. Excluding potential future severance costs while our strategic direction evolves, general and administrative expenses are expected to decrease in future periods.

Interest income for the three months ended September 30, 2024 and 2023 were $0.2 million and $0.5 million, respectively. The decrease of $0.3 million was primarily due to lower average cash and investments balances.

Grant revenue was $1.9 million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively. The increase of $1.4 million was primarily due to the timing of NIH grant activities.

The following table summarizes our research and development expenses for the periods indicated:

Research and development expenses for the nine months ended September 30, 2024 and 2023 were $19.1 million and $23.1 million, respectively. The decrease of $4.0 million was primarily due to a $2.5 million decrease in direct product candidate expenses and a $1.5 million decrease in unallocated research and development expenses.

Direct expenses for ONCT-534 increased $3.0 million for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to an increase in manufacturing and clinical activities associated with the initiation of our Phase 1/2 clinical study of ONCT-534 in the third quarter of 2023. Such study was discontinued in the latter part of the third quarter of 2024.

Direct expenses for ONCT-808 was $3.7 million for each of the nine months ended September 30, 2024 and 2023. Such study was discontinued in the latter part of the third quarter of 2024.

Direct expenses for zilovertamab decreased $5.7 million for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to lower clinical trial activity and manufacturing costs associated with the reprioritization of this program in April 2023. Such study activities terminated in the third quarter of 2024.

Direct expenses for ONCT-216 increased $0.3 million for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to 2023 expenses being offset by a $0.5 million sale of manufacturing materials to SPH USA. Costs incurred in the nine months ended September 30, 2024 were substantially offset by NIH revenue.

Unallocated research and development expenses decreased $1.5 million for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to lower personnel-related expenses, including non-cash stock-based compensation costs, resulting from our headcount reductions as the year-to-date accrued bonuses were reversed in total and only partially offset by severance costs incurred. Excluding potential future severance costs while our strategic direction evolves, unallocated research and development expenses are expected to decrease in future periods as our research and development activities are being discontinued with a reduced headcount.

General and administrative expenses for each of the nine months ended September 30, 2024 and 2023 were $9.1 million and $9.5 million, respectively. The decrease of $0.4 million was primarily due to lower corporate insurance expenses which were partially offset by higher intellectual property related legal expenses.

Interest income for the nine months ended September 30, 2024 and 2023 were $0.9 million and $1.8 million, respectively. The decrease of $0.9 million was primarily due to lower average cash and investment balances.

We have incurred losses and negative cash flows from operations since inception. As of September 30, 2024, we had an accumulated deficit of $223.2 million and anticipate that we will continue to incur net losses for the foreseeable future. As of September 30, 2024, we had $14.6 million in cash, cash equivalents and short-term investments and no debt. On September 12, 2024, we announced that our Board decided to discontinue our clinical trials evaluating ONCT-534 and ONCT-808 as well as all other product development activities. We also announced we were exploring strategic alternatives to maximize the value of our assets for our stockholders. We commenced a reduction-in-force beginning in September 2024, and will continue to assess further cost reduction measures as our operational and strategic direction evolves. As part of the review of strategic alternatives, we may consider options such as asset sales or out-licensing opportunities for existing programs and merger, reverse merger or other business combination opportunities. We will continue to incur research and development expenses in connection with clinical trial closing costs and the completion of certain ongoing and nonclinical research and manufacturing activities.

We believe the balance of cash, cash equivalents and short-term investments will not be sufficient to fund our projected operating requirements and meet our obligations for at least the twelve months following the financial statement issuance date without entering into one or more collaborations or raising additional funding, liquidating assets, or making changes to our operating plans or programs to reduce expenses. As a result, there is substantial doubt about our ability to continue as a going concern for twelve months following the issuance date of the condensed consolidated financial statements as of September 30, 2024. However, we believe that our cash, cash equivalents and short-term investments provide sufficient cash to fund our projected operating requirements into the first quarter of 2025.

In December 2021, we entered into an Open Market Sales AgreementSM ("Sales Agreement"), with Jefferies LLC, providing for the sale of up $50.0 million of our common stock from time to time in “at-the-market” ("ATM") offerings under our shelf registration statement on Form S-3 (No. 333-254985) (the “Prior Shelf Registration Statement”). During the nine months ended September 30, 2024 and 2023, we sold none and 55,274 shares of common stock for net proceeds of none and $1.2 million, respectively, pursuant to our ATM program. On April 2, 2024, the ATM program expired. On March 8, 2024, we filed a new shelf registration statement on Form S-3 (No. 333-277795) which was declared effective by the Securities and Exchange Commission on May 1, 2024.

The following table summarizes our sources and uses of cash for each of the periods presented:

Net cash used in operating activities was $20.2 million and $25.7 million for the nine months ended September 30, 2024 and 2023, respectively. The decrease in cash used in operating activities was primarily due to the reprioritization of the zilovertamab program in April 2023 as well as the timing of incurring expenses and payments, which were partially offset by increases in our spending on our two Phase 1/2 clinical studies. Net cash used in operating activities during the nine months ended September 30, 2024 was primarily due to our net loss of $25.4 million adjusted for $4.0 million of non-cash charges, primarily for stock-based compensation, which was partially offset by a $0.1 million change in operating assets and liabilities. Net cash used in operating activities during the nine months ended September 30, 2023 was primarily due to our net loss of $30.3 million adjusted for $4.2 million of non-cash charges, primarily for stock-based compensation, and a $0.4 million change in operating assets and liabilities.

During the nine months ended September 30, 2024, net cash provided by investing activities was $26.7 million consisting primarily of net maturities of available-for-sale securities. During the nine months ended September 30, 2023, net cash provided by investing activities was $2.5 million consisting primarily of net maturities of available-for-sale securities.

Net cash used in financing activities was $0.1 million for the nine months ended September 30, 2024 and net cash provided by financing activities was $1.1 million for the nine months ended September 30, 2023. The net cash used during 2024 resulted from common shares repurchased for tax withholding obligations related to the vesting of restricted stock units. The net cash provided during 2023 resulted primarily from the proceeds received from the sale of common stock under the ATM program.

On March 8, 2024, we filed a new shelf registration statement on Form S-3 (No. 333-277795) which was declared effective by the Securities and Exchange Commission on May 1, 2024. Under current SEC regulations, if at any time our public float is less than $75.0 million, and for so long as our public float remains less than $75.0 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the baby shelf rules. As of September 30, 2024, our calculated public float was less than $75.0 million. Future sales of our common stock, if any, will depend on a variety of factors including, but not limited to, the need for additional financing in connection with our review of strategic alternatives. There can be no assurance that we will be successful in consummating future sales of our securities based on prevailing market conditions or in the quantities or at the prices that we deem appropriate.

We are party to a number of license agreements, pursuant to which we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements. As of September 30, 2024, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. See Notes 4 and 5 to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of these agreements.

We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period and, therefore, are cancelable contracts.

Management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The preparation of the financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods.

Our estimates are based on our historical trends and other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. Certain service providers invoice us in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: (i) CROs and other third parties in connection with clinical studies and preclinical development activities; (ii) investigative sites in connection with clinical studies; and (iii) third parties related to product manufacturing, development and distribution of clinical supplies.

We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our

understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period.

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.

We maintain “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in the reports we file and submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting

Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

An investment in our securities involves a high degree of risk. You should carefully consider the specific factors discussed below, as well as all other information included in this Quarterly Report on Form 10-Q, including our financial statements, the notes thereto and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If any of the following risks actually occurs, our business, financial condition, operating results, prospects and ability to accomplish our strategic objectives could be materially harmed. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in our securities.

There have been no material changes to the risk factors included in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023, other than as follows:

We may not be successful in identifying and implementing any potential strategic alternatives in a timely manner, or at all, and any strategic transactions that we may consummate in the future could have negative consequences.

In September 2024, we announced that we were discontinuing our clinical studies and exploring strategic alternatives. We expect to devote substantial time and resources to exploring strategic alternatives that our Board believes will maximize stockholder value. Despite management devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that we will be able to successfully consummate any particular strategic transaction on attractive terms, on a timely basis, or at all. For example, certain types of strategic transactions may require third-party consents, such as stockholder approval, which could be difficult or costly to obtain. We have not set a timetable for completion of this strategic review process, and our Board has not approved a definitive course of action. Additionally, there can be no assurance that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value or that we will make any cash distributions to our stockholders.

The process of continuing to evaluate our strategic alternatives may be costly, time-consuming and complex, and we may incur significant legal, accounting and advisory fees and other expenses, some of which may be incurred regardless of whether we successfully enter into a transaction. We may also incur additional unanticipated expenses in connection with this process. Any such expenses will decrease the remaining cash available for use in our business. Our ability to pursue or consummate strategic transactions also depends upon our ability to retain certain of our employees, the loss of whose services may adversely impact the ability to identify, negotiate and consummate such transaction. If we are unable to successfully retain certain of our key remaining personnel, we are at risk of a disruption to our exploration and consummation of one or more strategic transactions.

In addition, potential counterparties in a strategic transaction involving us may place minimal or no value on our assets and our public listing. Further, should we resume the development of drug candidates, such as one or more of the programs in our pipeline for which we halted further development, the development and any potential commercialization of our drug candidates will require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving us may choose not to spend additional resources to resume or continue development of our future drug candidates and may attribute little or no value, in such a transaction, to our drug candidates.

In addition, any strategic transactions that we may pursue could have a variety of negative consequences, and we may enter into a transaction that yields unexpected results that adversely affect our business and decreases the remaining cash available for use in our business. Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us, obtaining stockholder approval and the availability of financing to third parties in a potential transaction with us on reasonable terms. There can be no

assurance that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, lead to increased stockholder value, or achieve the anticipated results.

If we are unsuccessful in pursuing a new strategic path, or if any plans are not executed in a timely fashion, this may cause reputational harm with our stockholders and the value of our securities may be adversely impacted. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of our company could cause our stock price to fluctuate significantly.

We may become involved in litigation, including securities class action litigation, that could divert our management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.

In the past in our industry, litigation, including securities class action litigation, has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events. These events may also result in investigations by the SEC. We may be exposed to such litigation even if no wrongdoing occurred. Litigation is usually expensive and diverts management’s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.

Our workforce reduction may not achieve our intended outcome and may result in significant adverse consequences.

In September 2024, in connection with our evaluation of strategic alternatives, our Board approved a reduction-in-force, which is intended to continue in stages as our operational and strategic direction evolves. This reduction-in-force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction-in-force. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction-in-force could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives, including any potential strategic alternatives. If we are unable to realize the anticipated benefits from the reduction-in-force, or if we experience significant adverse consequences from the reduction-in-force, our business, financial condition, and results of operations may be materially adversely affected.

Pursuant to Item 408(a) of Regulation S-K, none of our directors or executive officers adopted, terminated or modified a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended September 30, 2024.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


第一部分-財務資訊		3

項目一。	簡明綜合財務報表（未經審核）	3
	簡明綜合資產負債表	3
	簡明綜合營運報表及綜合損失	4
	簡明綜合現金流量報表	5
	簡明綜合股東權益表	6
	簡明綜合財務報表附註	8
項目二。	管理層對財務狀況及營運結果進行討論及分析	20
第三項目。	關於市場風險的定量和定性披露	29
第四項。	控制和程序	29

第二部分-其他資料		30

項目一。	法律程序	30
項目 1A。	風險因素	30
項目二。	非登記股份證券銷售	31
第三項目。	高級證券違約	31
第四項。	礦山安全披露	31
第五項。	其他資訊	31
第六項	展品	32

簽名		34


	九月三十日， 2024			12月31日， 2023

資產
流動資產:
現金及現金等價物	$	13,079		$	6,697
短期投資		1,499			27,558
預付及其他		869			1,804
全部流動資產		15,447			36,059
使用權資產		154			258
其他資產		—			412
資產總額	$	15,601		$	36,729
550,714
流動負債：
應付賬款	$	1,198		$	1,148
應付負債		5,064			3,877
租賃，流動		191			173
流動負債合計		6,453			5,198
延遲薪酬		—			1,334
租賃，扣除當前		—			145
總負債		6,453			6,677
負債和條件（附註4）
股東權益：
優先股，面額$0.01，授權股數為5,000,000股，發行且流通股數為截至2024年6月30日和2023年12月31日之184,668,188股和181,364,180股。0.001 面值，授權股份 – 5,000; issued shares – 無		—			—
0.010.001 par value; authorized shares – 120,000; issued and outstanding shares – 2,960以及 2,948 at September 30, 2024 and December 31, 2023, respectively		3			3
資本公積額額外增資		232,334			227,825
累積其他綜合收益		1			3
累積虧損		(223,190	)		(197,779	)
股東權益總額		9,148			30,052
負債和股東權益總額	$	15,601		$	36,729


	三個月已結束九月三十日						九個月已結束九月三十日
	2024			2023			2024			2023
補助金收入	$	494		$	179		$	1,864		$	488
運營費用：
研究和開發		6,448			7,475			19,119			23,083
一般和行政		2,727			3,094			9,068			9,483
運營費用總額		9,175			10,569			28,187			32,566
運營損失		(8,681	)		(10,390	)		(26,323	)		(32,078	)
利息收入		217			528			912			1,763
淨虧損	$	(8,464	)	$	(9,862	)	$	(25,411	)	$	(30,315	)
綜合收益（虧損）：
可供出售證券的未實現收益（虧損），淨額		4			6			(2	)		(9	)
綜合損失	$	(8,460	)	$	(9,856	)	$	(25,413	)	$	(30,324	)
基本和攤薄後的每股淨虧損	$	(2.86	)	$	(3.35	)	$	(8.58	)	$	(10.32	)
加權平均已發行股票、基本股和攤薄後股票		2,960			2,948			2,960			2,937


	九個月結束 9月30日,
	2024			2023
經營活動現金流
淨損失	$	(25,411	)	$	(30,315	)
調整爲淨損失到經營活動現金流量淨使用：
以股票爲基礎的補償		4,596			5,282
短期投資折扣的累增		(625	)		(1,266	)
非現金租賃費用		104			149
經營性資產和負債變動:
預付和其他資產		1,347			2,241
應付賬款		50			(784	)
應計負債		(280	)		(1,810	)
延期補償		133			856
47,918		(127	)		(98	)
經營活動使用的淨現金流量		(20,213	)		(25,745	)
投資活動現金流量
可供出售證券購買		(16,318	)		(52,541	)
可供出售證券的到期日		43,000			55,000
投資活動提供的淨現金流量		26,682			2,459
籌資活動現金流量
發行普通股收到的款項，淨額		—			1,224
爲支付稅收預留義務而回購普通股		(87	)		(155	)
籌集資金的淨現金流量		(87	)		1,069
現金及現金等價物淨減少		6,382			(22,217	)
期初現金及現金等價物餘額		6,697			37,142
期末現金及現金等價物	$	13,079		$	14,925
非現金籌資活動補充披露:
在交換運營租賃負債獲得的使用權資產	$	—		$	353


	2024年9月30日止三個月
	普通股					額外的實繳			累積的			累積的			總計股東的
	股份			數量		資本			綜合收益（損失）			$			股權
2024年6月30日餘額		2,960		$	3	$	230,480		$	(3	)	$	(214,726	)	$	15,754
可供出售證券的未實現損失		—			—		—			4			—			4
以股票爲基礎的補償		—			—		1,854			—			—			1,854
淨損失		—			—		—			—			(8,464	)		(8,464	)
2024年9月30日的餘額		2,960		$	3	$	232,334		$	1		$	(223,190	)	$	9,148



	2023年9月30日止三個月
	普通股					額外的實繳			累積的			累積的			總計股東的
	股份			數量		資本			綜合收益（損失）			$			股權
2023年6月30日的餘額		2,936		$	3	$	223,941		$	(6	)	$	(178,753	)	$	45,185
根據限制性股票單位的歸屬而發行的普通股		18			—		—			—			—			—
股份已回購，以支付最低法定稅款扣除額。		(6	)		—		(49	)		—			—			(49	)
可供出售證券未實現收益		—			—		—			6			—			6
以股票爲基礎的補償		—			—		1,717			—			—			1,717
淨損失		—			—		—			—			(9,862	)		(9,862	)
2023年9月30日結餘		2,948		$	3	$	225,609		$	—		$	(188,615	)	$	36,997


大型加速歸檔人	☐	加速歸檔人	☐
非加速歸檔人	☒	小型報告公司	☒
新興成長型企業	☐


	2024年9月30日止九個月
	普通股					額外的實繳			累積的			累積的			總計股東的
	股份			數量		資本			綜合收益			$			股權
2023年12月31日結餘爲		2,948		$	3	$	227,825		$	3		$	(197,779	)	$	30,052
根據限制性股票單位的歸屬而發行的普通股		19			—		—			—			—			—
股份回購用於結算最低法定稅款代扣		(7	)		—		(87	)		—			—			(87	)
以股票爲基礎的補償		—			—		4,596			—			—			4,596
可供出售證券的未實現損失										(2	)					(2	)
淨損失		—			—		—			—			(25,411	)		(25,411	)
2024年9月30日的餘額		2,960		$	3	$	232,334		$	1		$	(223,190	)	$	9,148


	2023年9月30日止九個月
	普通股					額外的實繳			累積的			累積的			總計股東的
	股份			數量		資本			綜合收益			$			股權
2022年12月31日結存餘額		2,874		$	3	$	219,257		$	9		$	(158,300	)	$	60,969
根據限制性股票單位的歸屬而發行的普通股		30			—		—			—			—			—
股票已回購，用於支付最低法定稅款扣除		(11	)		—		(155	)		—			—			(155	)
發行普通股，扣除發行成本後淨額爲$38		55			—		1,223			—			—			1,223
以股票爲基礎的補償		—			—		5,284			—			—			5,284
可供出售證券的未實現損失		—			—		—			(9	)		—			(9	)
淨損失		—			—		—			—			(30,315	)		(30,315	)
2023年9月30日結餘		2,948		$	3	$	225,609		$	—		$	(188,615	)	$	36,997


	Three Months Ended September 30,									Nine Months Ended September 30,
(in thousands)	2024			2023			Change			2024			2023			Change
Grant revenue	$	494		$	179		$	315		$	1,864		$	488		$	1,376
Operating expenses:
Research and development		6,448			7,475			(1,027	)		19,119			23,083			(3,964	)
General and administrative		2,727			3,094			(367	)		9,068			9,483			(415	)
Total operating expenses		9,175			10,569			(1,394	)		28,187			32,566			(4,379	)
Loss from operations		(8,681	)		(10,390	)		1,709			(26,323	)		(32,078	)		5,755
Interest income		217			528			(311	)		912			1,763			(851	)
Net loss	$	(8,464	)	$	(9,862	)	$	1,398		$	(25,411	)	$	(30,315	)	$	4,904


Exhibit		Incorporation by Reference
Number	Exhibit Description	Form	File no.	Exhibit No.	Filing Date

3.1	Restated Certificate of Incorporation of the Registrant dated March 4, 2024	10-K	000-50549	3.1	7-Mar-24

3.2	Amended and Restated Bylaws of the Registrant	8-K	000-50549	3.3	10-Jun-19

4.1	Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement dated May 19, 2020, between the Registrant and the purchasers signatory thereto (“May 2020 Purchase Agreement”)	8-K	000-50549	4.1	21-May-20

4.2	Form of Placement Agent Warrant, issued by Registrant pursuant to the May 2020 Purchase Agreement	8-K	000-50549	4.2	21-May-20

4.3	Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement dated July 17, 2020, between the Registrant and the purchasers signatory thereto (the “July 2020 Purchase Agreement”)	8-K	000-50549	4.1	21-Jul-20

4.4	Form of Placement Agent Warrant, issued by Registrant pursuant to the July 2020 Purchase Agreement	8-K	000-50549	4.2	21-Jul-20

4.5	Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated August 27, 2020, between the Registrant and H.C. Wainwright & Co., LLC (“H.C. Wainwright”)	8-K	000-50549	4.1	31-Aug-20

4.6	Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated November 17, 2020, between the Registrant and H.C. Wainwright	8-K	000-50549	4.1	19-Nov-20

4.7	Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated December 9, 2020, between the Registrant and H.C. Wainwright	8-K	000-50549	4.1	11-Dec-20

31.1*	Certification of Chief Executive Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2*	Certification of Chief Financial Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1‡	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2‡	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document

101.SCH*	Inline XBRL Taxonomy Extension Schema Document


104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


	Oncternal Therapeutics, Inc.

Date: November 6, 2024	By:	/s/ James B. Breitmeyer
		Name: James B. Breitmeyer
		Title: President and Chief Executive Officer

Date: November 6, 2024	By:	/s/ Richard G. Vincent
		Name: Richard G. Vincent
		Title: Chief Financial Officer